Analysis of high-dose tamoxifen therapy efficiency in complex treatment of patients with stage III-IV non-small cell lung cancer
DOI:
https://doi.org/10.14739/2310-1210.2012.6.18028Keywords:
non-small cell lung cancer, tamoxifen, receptors, estrogen, progesteron, chemohormonal treatmentAbstract
With the help of immunohistochemcial methods the frequency of estrogen and progesteron expression in tumor tissue of 30 patients with non-small cell lung cancer was analysed, positive result took place in 1 patient (3%). Assessment of effi ciency of high dose tamoxifenotherapy in combined treatment was performed in 45 patients with III-IV stages of non-small cell lung cancer (control group – 39 patients received chemotherapy only); the results obtained were signifi cantly better in achieving of partial regression and stabilization of the disease in the study group.
References
Рак легкого / Под ред. П. Логригана; пер. с англ. – М.: ООО «Рид Элсивер», 2009. – 196с.
Федоренко З.П. Рак в Україні / Федоренко З.П., Гулак Л.О., Горох Є.Л. та ін. // Бюлетень національного канцер-реєстру України. – Вид.12. – К., 2011.
Рак в Україні, 2010–2011 // Бюлетень національного канцер-реестру України. Видання № 13 / Гол. ред. Щепотін І.Б. – К., 2012.
Переводчикова Н.И. Место химиотерапии в системе лечения онкологических больных и выбор терапевтической тактики / Переводчикова Н.И. // Современная онкология. – 2001. – №2. – С. 66–73.
Тюляндин С.А. Перспективные подходы лекарственной терапии немелкоклеточного рака легкого / Тюляндин С.А. // Новое в терапии рака легкого. – М., 2003.
Bakir M. Is surgery indicated in patients with stage IIIa lung cancer and mediastinal nodal involvement? / Bakir M., Fraser S. et al. // Interact CardioVasc Thorac Surg. – 2011. – Vol. 13. – P. 303–310.
Christopher G. Azzoli Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer / Christopher G. Azzoli, Sarah Temin, Timothy Aliff et al. – Published online ahead of print at www.jco.org on September 6, 2011.
Горбунова В.А. Консервативное лечение рака легкого / Горбунова В.А., Маренич А.Ф., Михина З.П. – М.: Литтерра,
– 128 с.
Beattie C.W. Steroid receptors in human lung cancer / Beattie C.W., Hansen N.W., Thomas P.A. // Cancer Res. – 1985. –Vol.45. – P. 3206–4214.
Chandhuri P.K. Steroid receptors in human lung cancer / Chandhuri P.K., Thomas P.A., Walker M.J. et al. // Cancer Lett. – 1982. – Vol. 16. – P. 327–332.
Kobayashi S. Sex steroid receptors in diverse human tumors / Kobayashi S., Mizuno T., Tobioka N. et al. // Gann. – 1982. – №73 (3). – Р. 439–445.
Laura P. Stabile Combined Analysis of Estrogen Receptor b-1 and Progesterone Receptor Expression Identifi es Lung Cancer Patients with Poor Outcome / Laura P. Stabile, Sanja Dacic, Stephanie R. Land et al. // Clin Cancer Res. – 2011. – Vol. 17, №1. – P. 154–164.
Susan E. Olivo-Marston Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifi ers of nonsmall-cell lung cancer survival in both men and women / Susan E.Olivo-Marston, Leah E.Mechanic, Steen Mollerup et al. // Carcinogenesis. – 2010. – Vol. 31, №10. – P. 1778–1786.
Laura P. Stabile Human Non-Small Cell Lung Tumors and Cells Derived from Normal Lung Express Both Estrogen Receptor and ß and Show Biological Responses to Estrogen / Laura P. Stabile, Autumn L. Gaither Davis, Christopher T. Gubish et al. // Cancer Research. – 2002. – Vol. 62. – P. 2141–2150.
Apar Kishor Ganti Hormone Replacement Therapy Is Associated With Decreased Survival in Women With Lung Cancer / Apar Kishor Ganti, Abe E. Sahmoun, Amit W. Panwalkar et al. // Journal of Clinical Oncology. – 2006. – Vol. 24, №1. – P. 59–63.
Chen Y.M. Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer / Chen Y.M., Perng R.P., Yang K.Y. // Chung Hua I Hsueh Tsa Chih (Taipei). – 2000. – Vol. 63 (8). – P. 605–611.
Yang C.H. High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma / Yang C.H., Cheng A.L., Yeh K.H. // Cancer. – 1999. – Vol. 86 (3). – P. 415–420.
Gu W.Z. Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines / Gu W.Z., Chen Z., Tahir S.K. // Anticancer Drugs. – 1999. – Vol. 10. – P. 895–901.
Богуш Т.А. Перспективы применения тамоксифена в лечении солидных опухолей разной локализации, отличных от рака молочной железы / Богуш Т.А. – М., 2009.
Yeh K.H. High-dose tamoxifen reverses drug resistance to cisplatin and etoposide in a patient with advanced large cell carcinoma of lung / Yeh K.H., Cheng A.L. // Anticancer Res. – 1997. – Vol. 17, №2B. – P. 1341–1343.
Christopher G. Azzoli Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update
on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer /
Christopher G. Azzoli, Sarah Temin, Timothy Aliff et al. – Режим доступу: http://www.jco.org.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
